Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Avicidin advances to phase II

March 5, 1998

DiagnoCure signs agreements related to development of targeted nanoerythrosomes

March 4, 1998

Phase I/II trial results reported for OncoVax-P formulated with JenVax-100a

March 3, 1998

IDEC-Y2B8/rituximab combination enters phase III

Feb. 27, 1998

UCSF receives green light to develop new breast cancer therapy

Feb. 24, 1998

Maxamine progresses to phase III in AML

Feb. 23, 1998

Phase I trial results of DAB389IL-2 in lymphoma

Feb. 20, 1998

Seragen fusion toxin will get priority review

Feb. 5, 1998

Anti-ErbB3 antibodies described by Genentech in patent literature

Feb. 3, 1998

Proleukin cleared for marketing in U.S. for melanoma indication

Jan. 30, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...